Novel tracers and their development for the imaging of metastatic prostate cancer. - Wikidata - awgldk - TriplyDB

Novel tracers and their development for the imaging of metastatic prostate cancer.

Novel tracers and their development for the imaging of metastatic prostate cancer.

http://www.wikidata.org/entity/Q37321810

about

Positron emission tomography imaging of prostate cancer Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET Update on prostate imaging Imaging evaluation of prostate cancer with 18F-fluorodeoxyglucose PET/CT: utility and limitations 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo.Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression.Challenges in nuclear medicine: innovative theranostic tools for personalized medicine Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival.Can Choline PET Tackle the Challenge of Imaging Prostate Cancer?Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer PET/CT Imaging and Radioimmunotherapy of Prostate Cancer Imaging prostate cancer: an update on positron emission tomography and magnetic resonance imaging Functional imaging for prostate cancer: therapeutic implications.Molecular imaging of prostate cancer: PET radiotracers.Prostate specific membrane antigen- a target for imaging and therapy with radionuclides.Developing imaging strategies for castration resistant prostate cancer Choline intake and risk of lethal prostate cancer: incidence and survival.[18F]-2'-Fluoro-5-methyl-1-beta-D-arabinofuranosyluracil (18F-FMAU) in prostate cancer: initial preclinical observations.PET/CT in prostate cancer: non-choline radiopharmaceuticals.(18)F-fluorodeoxyglucose PET/CT for detection of disease in patients with prostate-specific antigen relapse following radical treatment of a local-stage prostate cancer.PET/CT and MRI in Bladder Cancer.Baseline 18F-FDG PET/CT parameters as imaging biomarkers of overall survival in castrate-resistant metastatic prostate cancer.Molecular imaging of prostate cancer with 18F-fluorodeoxyglucose PET.FDG PET in Prostate Cancer.Imaging metastatic bone disease from carcinoma of the prostate Quantitative 18F-fluorocholine positron emission tomography for prostate cancer: correlation between kinetic parameters and Gleason scoring.18F-fluorocholine for prostate cancer imaging: a systematic review of the literature.Prospects in radionuclide imaging of prostate cancer.The use and importance of liposomes in positron emission tomography.Lymph Node Staging with Choline PET/CT in Patients with Prostate Cancer: A Review.Prostate-specific membrane antigen-based imaging.11C-choline PET/CT and PSA kinetics.Strategies for imaging androgen receptor signaling pathway in prostate cancer: implications for hormonal manipulation and radiation treatment.Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET.Imaging and evaluation of patients with high-risk prostate cancer.New prospects for PET in prostate cancer imaging: a physicist's viewpoint.The clinical and therapeutic uses of MDM2 and PSMA and their potential interaction in aggressive cancers.NMR-based metabolomics of prostate cancer: a protagonist in clinical diagnostics.

P2860

Q24596241-BB606EF2-1796-4800-9FAB-6FF8B93DA5E2 Q24633858-F4BAE58A-9A8F-4B13-8627-4B9EC2CC4835 Q33908505-EA2D9876-7A3C-44FD-9C47-FAB37B0C44EC Q34035683-9EDC4387-3C48-487D-8A2E-7620AFFE452E Q34389457-E369DC8D-0D23-4AC5-A68F-7C8B28569550 Q34448553-2C0136CC-BBB5-4F78-8DD8-5415899C0DEE Q34995973-E0905122-AF45-4D36-914C-B151D40EC925 Q35093069-490FAF09-CEA7-482E-8EDC-C135DF3820FF Q35104505-04B2D788-AEBF-4895-8641-789FB89C0421 Q35597054-C7ADF47E-D488-4BAF-BC74-BCAD4A35A9A2 Q35849169-DC57D10B-0CD3-4408-BECC-E8622BA599D7 Q36033412-2C1CCFC5-E1B6-46F3-A95C-6B848355843A Q36085426-D5A75795-5110-458E-B442-E64D92E5DFA3 Q36125199-D6C7EBFD-C137-4745-9E07-E34BB720004D Q36128629-3B6EA1D4-6432-4CEE-8974-39371DE2965D Q36129937-5EBFAF6F-2743-460F-84FB-A25347E592AD Q36135685-5579F17A-5851-4C0D-9CED-AC1EC415DB2A Q36152211-7C2BE987-D05F-4FE9-9190-890EE7A8A1E9 Q36231643-6D2491D7-F7E0-4001-94E3-EEAD1FA98B15 Q36236041-E8F352C9-0180-4C1F-A51A-F11CBD266CA6 Q36308766-95F08012-4DDB-477B-A3C8-3B940A5206E4 Q36502692-ED81548C-AD9A-49FD-9BA0-223FDC4135BF Q36654987-9C721D66-1B56-433C-B21C-61BDE204E6FB Q37199286-5E009FC7-D490-4ED7-B3EF-F4928E6C5CDE Q37325974-83981178-9964-4C06-9E2D-6CB395B5A2B8 Q37352995-E3374C2B-E977-4343-8FCD-120899EB2573 Q37605543-64E8D3D8-A1E8-4EFC-983F-8C21C33DCC18 Q37714485-07CC2B54-14BA-4709-9D47-C4E79A21AE86 Q37918311-8A710FB6-BFF7-4181-BDD8-13E742CBADFE Q37962869-D43F21C8-5022-4C01-8E44-87C5941EF9EA Q37972659-D28D574E-FEF7-4082-AFD1-56D161EDF638 Q37973351-61F77B7D-5902-4001-84DC-EFABC9313FE7 Q38015617-1A3E3E2F-AEC2-4263-BA4A-1A4ADBC1CFBA Q38098442-4955AB77-5B77-4BEA-BDD5-B1C4BDE46C4B Q38167022-6107196F-F1D3-4ED1-AFE3-7C4D311B16E4 Q38606252-06873EB5-697F-4F15-9184-29DACDBE9E4F Q38611187-4454BB9C-9F2D-4179-B540-ED4D00C1DBEC Q38616392-16237607-C168-428E-AE0C-091B78682A64 Q38637803-A1A6136C-8EB7-4C03-8F36-1812E3448CCF Q38767020-663F584E-6FA7-4190-9F01-8A643F18BCD2

P2860

Novel tracers and their development for the imaging of metastatic prostate cancer.

http://www.wikidata.org/entity/Q37321810

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年学术文章

@wuu

2008年学术文章

@zh-cn

2008年学术文章

@zh-hans

2008年学术文章

@zh-my

2008年学术文章

@zh-sg

2008年學術文章

@yue

2008年學術文章

@zh

2008年學術文章

@zh-hant

name

Novel tracers and their development for the imaging of metastatic prostate cancer.

@en

Novel tracers and their development for the imaging of metastatic prostate cancer.

@nl

type

label

Novel tracers and their development for the imaging of metastatic prostate cancer.

@en

Novel tracers and their development for the imaging of metastatic prostate cancer.

@nl

prefLabel

Novel tracers and their development for the imaging of metastatic prostate cancer.

@en

Novel tracers and their development for the imaging of metastatic prostate cancer.

@nl

P1433

Q37321810-6074B1C0-56F8-4441-9697-278BDEB747C8

P1476

Q37321810-C01E7BB6-6240-4659-AE72-E7EF80A5225B

P2093

Q37321810-2A6814D0-0FDC-4806-A0A9-86ACD3927CC8

Q37321810-4A174CF4-2EB5-4416-91C6-D3A9AEA769B8

Q37321810-4ABE3735-0562-4A7D-9553-4583E107F439

P2860

Q37321810-012735E9-94EF-466C-9410-0B25A8484D2C

Q37321810-075B5CC1-A3AA-4857-963E-14E651FC7CE5

Q37321810-0860D077-4276-4B5F-8238-65B22347DD24

Q37321810-09A5F38E-FADF-4120-BBE2-683C5674C2D8

Q37321810-10B3273E-2CB8-4A5C-80BE-C70ED205F5A0

Q37321810-14F9F73C-D9B0-4E68-92A7-EE905BD91B3A

Q37321810-1DE591AF-BA5C-4022-94CA-B6F25257B517

Q37321810-20FE8711-69B9-4831-BE58-882E332231F5

Q37321810-259AE57E-A29E-4E1F-AC6C-E84E2F829B4F

Q37321810-2AFA45D1-3F64-4FC6-872C-499EA9C2BBE9

P304

Q37321810-6D267668-67D4-4FC1-8427-6286FD0C0073

P31

Q37321810-7F9D59CE-CD32-49B1-A5EC-BB0C0A6D879E

P356

Q37321810-8B3DA4CB-93C4-404B-AF3C-9B64AAC9B2FD

P407

Q37321810-8907E7CF-A70C-4EA2-B291-F80A481BAF46

P433

Q37321810-0E8D3CF3-782A-4791-9C84-7BDF4E65C546

P478

Q37321810-6334FCD8-2CB4-4C89-A284-B2D61009303D

P577

Q37321810-1F8B585A-5287-4B63-A735-3449E3B99BF2

P5875

Q37321810-C89B22A9-D8D5-4E5E-BE8D-27227126A12A

P698

Q37321810-E49E1573-9380-4B4F-B051-ECB7D1C15FFA

P932

Q37321810-1D381DD4-88C8-438A-997D-10C2EB461479

P356

JNUMED.108.050658

P1433

The Journal of Nuclear Medicine

P1476

Novel tracers and their development for the imaging of metastatic prostate cancer.

@en

P2093

Andrea B Apolo

http://www.w3.org/2001/XMLSchema#string

Michael J Morris

http://www.w3.org/2001/XMLSchema#string

Neeta Pandit-Taskar

http://www.w3.org/2001/XMLSchema#string

P2860

Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature

Validation of [1-11C]acetate as a tracer for noninvasive assessment of oxidative metabolism with positron emission tomography in normal, ischemic, postischemic, and hyperemic canine myocardium

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Molecular biology of bone metastasis.

Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer.

The role of positron emission tomography in skeletal disease.

Tumour phospholipid metabolism.

Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

P304

2031-2041

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2967/JNUMED.108.050658

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P577

2008-11-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23461587

http://www.w3.org/2001/XMLSchema#string

P698

18997047

http://www.w3.org/2001/XMLSchema#string

P932

3310891

http://www.w3.org/2001/XMLSchema#string